Mylan will pay $465 million to resolve False Claims Act liability

Mylan, maker of the EpiPen, has agreed to pay $465 million to settle Department of Justice allegations that it violated the False Claims Act by misclassifying the epinephrine injector  as a generic drug to avoid paying Medicaid rebates.

lock iconTHIS IS MEMBERS-ONLY CONTENT. To continue reading, choose one of the options below.